| 000B49 |
Franck Morschhauser [France] ; Olivier Fitoussi [France] ; Corinne Haioun [France] ; Catherine Thieblemont [France] ; Hang Quach [Australie] ; Richard Delarue [France] ; Sylvie Glaisner [France] ; Jean Gabarre [France] ; André Bosly [Belgique] ; John Lister [États-Unis] ; JU LI [États-Unis] ; Bertrand Coiffier [France] | A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial |
